Neoproct Yhdistelmäpakkaus (Fluocortolone Pivalate, Anhydrous Lidocaine Hydrochloride)

Fluocortolone pivalate is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors. This interaction alters gene transcription, leading to reduced production of inflammatory mediators, decreased leukocyte infiltration, and stabilization of cell membranes, thereby diminishing swelling and pain in the treated area.

The appropriate dose and frequency of Neoproct Yhdistelmäpakkaus are determined by the prescribing healthcare professional based on the severity of the condition, patient age, and response to therapy. Patients should follow the specific instructions provided by their prescriber and not alter the regimen without medical advice.

Safety data for fluocortolone pivalate and lidocaine hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using this product.

To request Neoproct Yhdistelmäpakkaus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neoproct Yhdistelmäpakkaus combines a potent corticosteroid (fluocortolone pivalate) with a local anaesthetic (lidocaine), offering both anti‑inflammatory and pain‑relieving actions in a single formulation. Compared with products that contain only a corticosteroid such as hydrocortisone, Neoproct may provide faster symptom relief due to the added anaesthetic effect, though the choice depends on clinical judgment.

Store Neoproct Yhdistelmäpakkaus below 25 °C in its original packaging, protecting it from moisture, direct sunlight, and excessive heat. Keep the product out of reach of children and avoid exposing it to temperatures that could compromise its stability.

Neoproct Yhdistelmäpakkaus is applied rectally, typically using a supplied applicator or a clean fingertip. The prescribed amount is gently inserted into the rectal canal, ensuring even distribution over the affected mucosa. Patients should follow the exact administration instructions given by their healthcare provider.

Serious adverse events, although rare, can include severe allergic reactions (anaphylaxis), rectal ulceration or tissue necrosis, systemic corticosteroid effects such as adrenal suppression, persistent numbness, and secondary infections at the application site. Any of these symptoms require immediate medical attention.

Neoproct Yhdistelmäpakkaus should be avoided in individuals with known hypersensitivity to fluocortolone pivalate, lidocaine, or any excipients in the formulation. It is also contraindicated on severely infected, ulcerated, or necrotic rectal tissue, and in patients for whom systemic corticosteroid exposure is contraindicated without close medical supervision.